9/27/26
CVS - Jessica Stine PharmD

Re: Practice information addressing two dispensing concerns — Accurate Clinic

Dear Jessica Stine PharmD,

Thank you for your diligence and our shared commitment to safe, appropriate opioid dispensing. Enclosed are two brief letters that respond, individually, to the two concerns raised regarding my prescriptions. They are provided so that each concern can be reviewed on its own terms.

- **Enclosure 1 — Travel distance ("50-mile") question.** Answers the question of why so many of my patients travel more than 50 miles to my practice — the limited rural specialist access in Louisiana and the specific, comprehensive, integrative services I provide that are not otherwise available in the state. It then addresses the 50-mile figure directly: it is a reasonable trigger for further inquiry, but not a metric that should be applied against a practice absent an actual finding, consistent with the 2022 CDC guideline and common sense.
- **Enclosure 2 — High-dose immediate-release pill-count concern.** Explains why my mean MME and immediate-release quantities (e.g., 180 tablets/month) are the predictable result of my case mix and long-tenured, intervention-failed patient population, why the 2022 CDC guideline directs individualized rather than threshold-based decisions, and how my monitoring directly addresses diversion concerns.

Both letters reflect a practice built on individualized assessment, monthly reassessment, PMP review, toxicology monitoring, documented functional benefit, and naloxone co-prescribing. I fully support a pharmacist's duty to confirm the legitimacy of a prescription, and I welcome the opportunity to resolve any red flag directly.

Please contact me with any question or concern about a specific patient or prescription. I am readily available and glad to provide additional documentation.

Respectfully,

Eric Ehlenberger MD
Accurate Clinic
Phone/Fax. 504.273.3004
Doctor@AccurateClinic.com

Enclosures (2):

(1) Letter — Why patients travel to my practice and the 50-mile question;
(2) Letter — High-dose immediate-release pill counts